link
Bookmarks
Pediatric Somatostatin Receptor-Positive Tumors
Andrew T. Trout, MD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe
0
0
0
0

KEY FACTS

  • Imaging

    • Top Differential Diagnoses

      • Pathology

        • Diagnostic Checklist

          TERMINOLOGY

          • Definitions

            • Pediatric type 2 somatostatin receptor (SSTR2)-positive tumors
              • Includes gastroenteropancreatic neuroendocrine tumors, pulmonary carcinoid, paraganglioma, neuroblastoma, sarcomas, and CNS tumors

          IMAGING

          • Imaging Recommendations

            DIFFERENTIAL DIAGNOSIS

              PATHOLOGY

              • General Features

                CLINICAL ISSUES

                • Treatment

                  DIAGNOSTIC CHECKLIST

                  • Image Interpretation Pearls

                    Selected References

                    1. Gaiani F et al: Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature. Medicine (Baltimore). 98(37):e17154, 2019
                    2. Torun N: 68Ga-DOTA-TATE in neuroblastoma with marrow involvement. Clin Nucl Med. 44(6):467-8, 2019
                    3. Jha A et al: Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 45(5):787-97, 2018
                    4. Kong G et al: Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. J Pediatr Hematol Oncol. 38(2):87-96, 2016
                    5. Lastoria S et al: Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. 52(3):488-94, 2016
                    6. Machado JS et al: Recommended administered activities for (68)Ga-labelled peptides in paediatric nuclear medicine. Eur J Nucl Med Mol Imaging. 43(11):2036-9, 2016
                    7. Gains JE et al: 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 52(7):1041-7, 2011
                    8. Menda Y et al: Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med. 51(10):1524-31, 2010
                    Related Anatomy
                    Loading...
                    Related Differential Diagnoses
                    Loading...
                    References
                    Tables

                    Tables

                    KEY FACTS

                    • Imaging

                      • Top Differential Diagnoses

                        • Pathology

                          • Diagnostic Checklist

                            TERMINOLOGY

                            • Definitions

                              • Pediatric type 2 somatostatin receptor (SSTR2)-positive tumors
                                • Includes gastroenteropancreatic neuroendocrine tumors, pulmonary carcinoid, paraganglioma, neuroblastoma, sarcomas, and CNS tumors

                            IMAGING

                            • Imaging Recommendations

                              DIFFERENTIAL DIAGNOSIS

                                PATHOLOGY

                                • General Features

                                  CLINICAL ISSUES

                                  • Treatment

                                    DIAGNOSTIC CHECKLIST

                                    • Image Interpretation Pearls

                                      Selected References

                                      1. Gaiani F et al: Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature. Medicine (Baltimore). 98(37):e17154, 2019
                                      2. Torun N: 68Ga-DOTA-TATE in neuroblastoma with marrow involvement. Clin Nucl Med. 44(6):467-8, 2019
                                      3. Jha A et al: Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 45(5):787-97, 2018
                                      4. Kong G et al: Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. J Pediatr Hematol Oncol. 38(2):87-96, 2016
                                      5. Lastoria S et al: Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. 52(3):488-94, 2016
                                      6. Machado JS et al: Recommended administered activities for (68)Ga-labelled peptides in paediatric nuclear medicine. Eur J Nucl Med Mol Imaging. 43(11):2036-9, 2016
                                      7. Gains JE et al: 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 52(7):1041-7, 2011
                                      8. Menda Y et al: Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med. 51(10):1524-31, 2010